Expression of histone methyltransferase SMYD3 in endometrial carcinoma and its significance

YE Wei-biao; LI Guang-liu; ZHU Ying; XUAN Wen-ting; LI Zhong-jun

doi:10.19538/j.fk2025100115

PDF(3573 KB)

Chinese Journal of Practical Gynecology and Obstetrics ›› 2025, Vol. 41 ›› Issue (10) : 1031-1033. DOI: 10.19538/j.fk2025100115

Expression of histone methyltransferase SMYD3 in endometrial carcinoma and its significance

Author information +

History +

Abstract

Objective To investigate the expression and significance of histone methyltransferase SMYD3 in endometrial carcinoma. Methods Totally 85 patients with endometrial cancer who underwent surgical treatment at The Tenth Affiliated Hospital，Southern Medical University from January 2014 to December 2020 were selected.The expression of SMYD3 in endometrial carcinoma tissue，atypical endometrial hyperplasia tissue，and normal endometrium tissue was assessed by immunohistochemical staining. The correlation between SMYD3 expression and clinicopathological characteristics and prognosis of patients was analyzed. Results The positive rate of SMYD3 expression in the endometrial carcinoma tissue was 83.53%，which was higher than that in atypical endometrial hyperplasia tissue（43.33%） and normal endometrium tissue （26.67%），and the difference was statistically significant （P<0.05）. The expression level of SMYD3 was associated with FIGO stage，lymphovascular space involvement，and lymph node metastasis in patients with endometrial carcinoma （P<0.05）. The patients with higher SMYD3 expression had shorter overall survival time than those with lower SMYD3 expression（P<0.05）. Conclusion The expression of SMYD3 is high in endometrial carcinoma，which is closely correlated with tumour progression and poor prognosis，suggesting that it can be used as a potential prognostic indicator and therapeutic target.

Key words

histone methyltransferase / SMYD3 / endometrial carcinoma

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

YE Wei-biao , LI Guang-liu , ZHU Ying , et al . Expression of histone methyltransferase SMYD3 in endometrial carcinoma and its significance[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2025, 41(10): 1031-1033 https://doi.org/10.19538/j.fk2025100115

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	胡兆星, 张运征, 董莹莹, 等. 人工智能辅助下的子宫内膜癌诊疗新理念与新视角[J]. 中国实用妇科与产科杂志, 2025, 41(8):859-864. DOI:10.19538/j.fk2025080119. Cited in this article [2]

[2]	中国抗癌协会子宫体肿瘤专业委员会, 中国妇产科精准医学协会,长三角地区妇科质控委员会.子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6): 626-637. DOI: 10.19538/j.fk2024060113. Cited in this article [1]

[3]	Li B, Pan R, Zhou C, et al. SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer[J]. Future Oncol, 2018, 14(18): 1825-1834. DOI: 10.2217/fon-2017-0682. Cited in this article [1]

[4]	Yoshioka Y, Suzuki T, Matsuo Y, et al. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization[J]. Cancer Med, 2017, 6(7): 1665-1672. DOI: 10.1002/cam4.1099. Cited in this article [1]

[5]	Tsai CH, Chen YJ, Yu CJ, et al. SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation[J]. Cancer Res, 2016, 76(20):6043-6053. DOI: 10.1158/0008-5472.CAN-16-0500. Cited in this article [1]

[6]	Lyu T, Jiang Y, Jia N, et al. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters[J]. Int J Cancer, 2020, 146(6):1553-1567. DOI: 10.1002/ijc.32673. Cited in this article [1]

[7]

Beck

, Weikel

, Brumm

, et al. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA,PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC)[J]. Gynecol Oncol, 1994, 53(2):220-227. DOI:10.1006/gyno.1994.1119.

Cited in this article [1]

[8]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231. DOI:10.3760/cma.j.cn112152-20240119-00035. Cited in this article [1]

[9]	杨婧, 李蓉. 子宫内膜增生症和早期子宫内膜癌患者的控制性超促排卵策略研究进展[J]. 中国实用妇科与产科杂志, 2024, 40(5):566-569. DOI:10.19538/j.fk2024050118. Cited in this article [1]

[10]	Hamamoto R, Saloura V, Nakamura Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis[J]. Nat Rev Cancer, 2015, 15(2):110-124. DOI:10.1038/nrc3884. Cited in this article [1]

[11]	Rubio-Tomás T. The SMYD family proteins in immunology:An update of their obvious and non-obvious relations with the immune system[J]. Heliyon, 2021, 7(6):e07387. DOI:10.1016/j.heliyon.2021.e07387. Cited in this article [1]

[12]	Fenizia C, Bottino C, Corbetta S, et al. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer[J]. Nucleic Acids Res, 2019, 47(3):1278-1293. DOI:10.1093/nar/gky1221. Cited in this article [1]

[13]	Zhu Y, Zhu MX, Zhang XD, et al. SMYD 3 stimulates EZR and LOXL2 transcription to enhance proliferation,migration,and invasion in esophageal squamous cell carcinoma[J]. Hum Pathol, 2016, 52:153-163. DOI: 10.1016/j.humpath.2016.01.012. Cited in this article [1]

[14]	Sarris ME, Moulos P, Haroniti A, et al. Smyd3 Is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development[J]. Cancer Cell, 2016, 29(3):354-366. DOI:10.1016/j.ccell.2016.01.013. Cited in this article [1]

[15]	Jiang Y, Lyu T, Che X, et al. Overexpression of SMYD3 in ovarian cancer is associated with ovarian cancer proliferation and apoptosis via methylating H3K4 and H4K20[J]. J Cancer, 2019, 10(17):4072-4084. DOI:10.7150/jca.29861. Cited in this article [1]

[16]	Huang Y, Tang M, Hu Z, et al. SMYD3 promotes endometrial cancer through epigenetic regulation of LIG4/XRCC4/XLF complex in non-homologous end joining repair[J]. Oncogenesis, 2024, 13(1):3-15. DOI:10.1038/s41389-023-00503-0. Cited in this article [1]